• Nouscom closed an oversubscribed EUR 120 million (USD 135 million) Series D financing.
• M Ventures and Revelation Partners co-led the round, with participation from existing investor 5AM Ventures and other new and existing investors.
• The clinical-stage biotech develops next-generation immunotherapies focused on cancer interception.
• Proceeds will advance NOUS-209, its investigational off-the-shelf neoantigen-based cancer immunotherapy, through a global registration-enabling trial in Lynch syndrome carriers.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 5AM Ventures LLC published the original content used to generate this news brief on October 19, 2026, and is solely responsible for the information contained therein.